Bloating and gas on Foundayo™

Distension and flatulence in Table 1

Table 1 of section 6.1 covers 3,155 adults on Foundayo™ and 1,576 on placebo from Trials 1 and 2, treated for up to 72 weeks ^[1]. To appear in it, a reaction had to affect at least 5% of treated adults and be more frequent than on placebo. Flatulence on 5.5 mg sits exactly on that line.

The Medication Guide turns the two rows into everyday words, a swollen belly and gas, and places both among the most common side effects ^[2]. No EMA product information exists yet for Foundayo™, despite a positive opinion in October 2026, so there is no European frequency band for either term, and Health Canada’s database has no entry ^[3][4].

Smaller numbers, consistent direction

Compared with nausea or constipation, these are modest figures: fewer than one in ten people on any dose ^[1]. Still, the direction is the same in every column. Distension ran about two to three times the placebo rate, flatulence about two and a half to three times. Neither rose much beyond 9 mg. Both belong to a much larger group: stomach and bowel reactions of any kind were reported by 60% on 5.5 mg, 68% on 9 mg and 69% on 17.2 mg, compared with 37% on placebo ^[1].

The two rows may overlap with each other and with others in the table, such as belching or indigestion. The label counts reactions separately and gives no combined figure for “bloating” as most people use the word ^[1].

Trial by trial, and against oral semaglutide

ClinicalTrials.gov splits the label pool into ATTAIN-1, without diabetes, and ATTAIN-2, with type 2 diabetes, at trial doses of 6, 12 and 36 mg that the label presents as Foundayo™ 5.5, 9 and 17.2 mg ^[1][5][6]. ACHIEVE-3 compared orforglipron 12 and 36 mg with oral semaglutide 7 and 14 mg for 52 weeks in type 2 diabetes treated with metformin ^[7][8]. All three entries list only events seen in at least 5% of a group ^[5][6][7].

Reading the registry rows

• Distension was roughly double placebo in both ATTAIN trials, and in ATTAIN-2 it hardly changed across the three doses ^[5][6].
• Gas was more common in ATTAIN-2 than in ATTAIN-1 at every orforglipron dose, and placebo was slightly higher there too; the registries do not explain the difference ^[5][6].
• In ACHIEVE-3, distension was more common on either orforglipron dose than on either semaglutide dose, yet gas on orforglipron 36 mg was lower than on 12 mg. With a 5% listing rule and open-label treatment, gaps this small call for caution ^[7][8].
• The ACHIEVE-3 authors reported stomach and bowel events overall in 59% and 58% on orforglipron against 37% and 45% on semaglutide ^[8]. The trial was in type 2 diabetes, which the US Foundayo™ label does not cover ^[1].

Possible reasons for the swelling

• From the label: Foundayo™ delays stomach emptying, most after the first dose and less over time, and it reduces food intake, likely by lowering appetite ^[1]. The label does not tie distension or gas to either effect and gives no timeline for them.
• Plausible but not measured: Cleveland Clinic explains that digestive contents can build up when the muscles that move them along are not working properly, as in gastroparesis ^[11], and constipation, a common Foundayo™ reaction, is a bloating cause in both the NIDDK and Cleveland Clinic lists ^[9][11]. No orforglipron study has checked whether either route explains the distension figures.
• General background: gas enters the gut through swallowed air and is made when bacteria in the large intestine break down carbohydrates that were not fully digested ^[9]. Some people feel bloated with a normal amount of gas, which Cleveland Clinic calls visceral hypersensitivity ^[11].

Everyday and medical causes besides the tablet

NIDDK and Cleveland Clinic list many causes that have nothing to do with orforglipron ^[9][11]:

• Swallowing more air: chewing gum, hard sweets, fizzy drinks, eating or drinking quickly, smoking and loose dentures.
• Carbohydrates the small intestine does not fully digest, as in lactose or fructose intolerance, or wheat and beans in sensitive people.
• Irritable bowel syndrome and other gut-brain disorders, small intestinal bacterial overgrowth, coeliac disease, reflux disease and gastroparesis.
• Hormonal shifts around periods, pregnancy and perimenopause, physical inactivity and side effects of other medicines.
• Less often, fluid in the abdomen (ascites), pancreatic insufficiency, inflammatory bowel disease or certain cancers, including ovarian, colon and pancreatic cancer.

When bloating is not routine

Section 6.2 lists ileus and intestinal obstruction among reports collected after approval of GLP-1 receptor agonists as a class ^[1]. These are reports without a known rate and are not from the Foundayo™ trials. They are the reason a severely swollen, painful abdomen should not be written off as ordinary wind.

In the registries, two people in ATTAIN-2 had a serious intestinal blockage, one on 6 mg and one on 12 mg, against none of 628 on placebo ^[6]; ACHIEVE-3 recorded one, on oral semaglutide 7 mg ^[7]. Single cases in groups of several hundred cannot show whether the tablet raises the risk.

MedlinePlus lists a swollen abdomen, fullness and gas, cramping pain, constipation or diarrhea, vomiting and being unable to pass gas among the symptoms of a blocked bowel ^[12]. Section 5.3 adds that stomach and bowel reactions on Foundayo™ are sometimes severe, at about 3% on orforglipron against 1% on placebo, and pancreatitis in section 5.2 can begin with severe abdominal pain ^[1].

Easing gas and bloating: what NIDDK and Cleveland Clinic describe

NIDDK’s first step is swallowing less air: skipping gum, hard sweets, fizzy drinks and straws, not talking while eating, and eating slowly while sitting down ^[10]. It also describes smaller, more frequent meals and cutting back on foods that raise your own gas, such as broccoli, cauliflower, beans, lentils, foods rich in fibre, fructose or lactose, and sweeteners whose names end in “-ol” ^[10].

Cleveland Clinic adds walking and other regular activity to help move gas along, avoiding long periods of sitting, chewing thoroughly, stopping before you feel full and keeping a food journal to spot triggers ^[11]. It notes that fibre-rich foods can cause more gas at first ^[11].

Both sources mention over-the-counter products, and NIDDK asks you to talk with a doctor before trying supplements or probiotics ^[10]. Because Foundayo™ slows stomach emptying and can change how other oral medicines are absorbed ^[1], a pharmacist should check any gas or bloating remedy you add.

Open questions in the Foundayo™ data

• There is no single figure for bloating as people use the word; distension, gas, belching and indigestion are counted one by one ^[1].
• There is no timing for distension or gas, and no data on whether they fade ^[1].
• No analysis looks at meal size or diet, so whether large meals matter more on orforglipron is untested.
• Belching and constipation, the two neighbouring reactions, have their own Foundayo™ pages on this site.

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.